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Abstract
Background: The goal of newborn screening is early identification of babies with a high risk for disorders that may
not be clinically evident at birth, but have severe consequences if untreated. New insight into inherited diseases
and the ability to test for numerous diseases using new technique such as tandem mass spectrometry have made
it practical to greatly expand the number of conditions tested. The expanded neonatal screening is now available
and relatively simple, but this represents only a part of the picture. Positive results require follow-up confirmation.
Most disorders screened require confirmatory biochemical or genetic tests and specialist visits. An efficient system
is needed for managing the care of affected newborns. Expanded newborn screening is not yet available in all
Regions of Italy, but discussions aimed at organizing universal access are underway. If these are successful, the
role of the pediatrician as the primary contact with the parents is expected to become even more important.
Methods: We have conducted a survey of Italian pediatricians to assess their familiarity and opinions on newborn
screening in general and on expanded newborn screening. All members of the Italian Association of Pediatricians
(n = 9000) were invited to compile a 10-item questionnaire online.
Results: The response rate was 10 %, corresponding to 605 of 6000 active members. Respondents were from all
Regions of Italy, with the highest number of responses coming from Lombardy (138, 22.8 %), Campania and Puglia
(n = 61; 10.1 %). Interestingly, expanded neonatal screening was not available in any of these Regions at the time of
the survey. Regarding their understanding of neonatal screening in general, most respondents (n = 552; 91.1 %)
considered that they had at least a sufficient level of knowledge; however, only 59.6 % thought they had sufficient
knowledge of expanded newborn screening.
Conclusions: Successful implementation of a universal expanded NBS program will require efficient procedures for
follow-up, diagnosis and treatment to prevent morbidity and mortality of infants and to reduce the period of uncertainty
for unaffected families. Pediatricians may need additional training to allow them to fulfill their tasks of coordinating this
process while keeping families informed and reassured.
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Background
The goal of newborn screening (NBS) is early identification
of babies with a high risk for disorders that may not be clin-
ically evident at birth, but have severe consequences if un-
diagnosed and untreated. The prototypical condition is
phenylketonuria [1], which is initially asymptomatic, but
leads to severe irreversible mental impairment if not treated
promptly. Alongside vaccination programs, NBS programs
represent one of the great public health success stories, im-
proving outcomes and reducing the burden to patients,
families and society. In Italy, neonatal screening for phenyl-
ketonuria, congenital hypothyroidism, and cystic fibrosis
has been mandatory by law since 1992.
New insight into inherited diseases combined with the
introduction of tandem mass spectrometry (MS-MS) and
the ability to test for numerous diseases using a fast and re-
liable analysis has led to expansion of the number of condi-
tions tested. Many of the diseases amenable to screening
are rare inborn errors of metabolism resulting from a gen-
etic defect that affects an enzyme active in one or more
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metabolic pathways. These defects cause pathological accu-
mulation of substrates or deficiencies of essential products.
Many are involved in the metabolism of fatty acids, organic
acids or amino acids/urea cycle [2]. The majority of these
disorders present clinical symptoms in the neonatal period
and the conditions cause progressive irreversible damage.
Criteria have been established to select disorders for in-
clusion (Additional file 1) [3, 4]. Factors to be taken into
consideration are disease morbidity, mortality, natural his-
tory and epidemiology; test reliability, precision, clinical
validity, cost, and the existence of confirmatory tests;
treatment availability, effectiveness and the availability of
medical expertise. Continuous improvements in treat-
ment, in particular the introduction of enzyme substitu-
tion therapies and the prospect of gene therapy may
further increase the number of diseases included in
screening panels. Discussion is currently ongoing on
whether to include lysosomal storage diseases in routine
screening [5, 6].
At the international level, there is a high level of hetero-
geneity regarding the decision to conduct expanded NBS
and the composition of screening panels [7–10], and there
are also examples of considerable regional heterogeneity
within countries. In Italy, newborn screening programs
are managed at the regional level. Italian Law 104/1992,
DPCM of July 9, 1999 mandates newborn screening for
phenylketonuria, congenital hypothyroidism and cystic
fibrosis, but it also allows the possibility for individual
regions to organize screening programs for additional
congenital diseases, and screening programs for endo-
crinopathies and inborn errors of metabolism are per-
formed in some Italian Regions.
Currently, there is substantial dishomogeneity among
Italian Regions regarding the implementation of screening
programs. Several Regions have expanded screening pro-
grams in place that cover 20 to 40 rare diseases (Tuscany,
Umbria, Liguria, Sardinia, Emilia Romagna, Sicily, Veneto),
while some other have experimental programs ongoing
(Lazio). In all, about one third of newborns currently
undergo expanded screening in Italy. Discussions and plan-
ning are underway to introduce it uniformly in all regions.
There is need for shared criteria for selecting diseases to
screen for and an analysis of possible synergies for the most
efficient management of this task and the steps that must
follow when a positive screening result is obtained. The
screening itself is part of a program in which blood spot
analysis represents only the initial part of the picture. To
insure adequate analytical sensitivity, there is a consistent
number of false positive results that require follow-up con-
firmation. Most of the disorders screened require confirma-
tory biochemical or genetic tests and specialist visits. When
affected newborns are identified, there must be an efficient
system for managing their condition. With the introduction
of expanded NBS, there will be more positive results (both
true and false) and the role of the pediatrician as the pri-
mary contact with the parents is expected to become even
more important.
Recommendations on expanded screening from the
SISMME and SISN [11] indicate that primary care pediatri-
cians should be familiar with the screening procedure and
with diseases that are included in the panel. They should
also maintain contacts with the local screening facility and
the appropriate specialist care providers, and interact dir-
ectly with the affected families to keep them informed.
Pediatric specialists, on the other hand, should organize the
follow-up of patients with positive screening results and
share the results with the primary pediatrician. They should
also coordinate diagnostic and therapeutic efforts of other
specialists, and set up the long-term treatment strategy with
the primary pediatrician and the family. It is clear that pedi-
atricians have an important role in the process that will
grow if universal coverage is established.
We report the results of a survey conducted among pe-
diatricians from all regions of Italy regarding their know-
ledge and impression of the concept of NBS in pediatrics,
focusing on diagnosis, treatment and healthcare resource
management.
Methods
An invitation to participate in the web-based survey was
sent to all 9000 members of the Italian Pediatrics Society
(SIP). The survey questionnaire was developed by the
Authors and consisted of ten questions to gauge famil-
iarity with the principles of NBS and how they apply to
the pediatrician’s Region (see below). Questions were in-
cluded to confirm also the understanding of criteria for
selecting diseases to include in the extended panel and
the principle characteristics of extended screening.
Questionnaire on the concept of neonatal screening in
pediatrics
1. How would you define your knowledge regarding
neonatal screening? (poor, insufficient, sufficient,
appropriate)
2. Is neonatal screening performed in your Region?
(yes, no, I don’t know)
3. Indicate which region you live in. (Choose from list)
4. Which conditions are screened in your Region?
(phenylketonuria and hypothyroidism; cystic fibrosis,
galactosaemia, biotinidase deficiency, maple syrup
urine disease, congenital adrenal hyperplasia, I don’t
know)
5. How would you define your knowledge of expanded
newborn screening for inherited metabolic diseases?
(poor, insufficient, sufficient, appropriate)
6. Is expanded neonatal screening performed in your
Region? (yes, no, I don’t know)
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7. Do you think that expanded newborn screening
should be required by law? (yes, no, I don’t know)
8. Indicate up to three criteria that a disease should
have to be eligible for early detection in a screening
program.
 It must be possible to diagnose the disease in the
initial phase.
 These are primarily common diseases that are
preventable.
 Treatment in the early phase must be more
efficacious than that in later phases.
 The possibility of performing the test at any time
during preschool age.
 The test should be readable in any Analytical
Laboratory.
 The costs must be balanced by the benefits.
9. Indicate two of the main characteristics of expanded
neonatal screening:
 Discover the presence of the disease at the first
emergence of symptoms
 Diagnose a disease also in the absence of evident
symptoms
 The test uses methods that are complicated and
expensive
 The test must be performed during the first days
after birth
 The test must be performed in the first year after
birth
10.Are there reference Centers for treating metabolic
disorders in your Region? (yes, no, I don’t know)
Results and discussion
Surveys were compiled by 605 pediatricians representing
all Regions of Italy. The response rate was 10 % of 6000
active members. Detailed results are available in the sup-
plemental material (http://surveys.biomedia.net/screening-
chart.html). Respondents were from all Regions of Italy,
with the largest number, about one fifth, residing in
Lombardy (n = 138, 22.8 %); Valle d’Aosta registered a
single respondent. Many respondents (44.1 %) reported
living in Regions where expanded screening is carried out;
however, this number may include regions with partial
coverage or where experimental programs are in place.
Newborn screening
Most respondents (99 %) indicated correctly that neonatal
screening is performed in their Region. In fact, basic NBS
is mandatory in Italy. Regarding their understanding of
neonatal screening in general, most respondents consid-
ered that they had at least a sufficient level of knowledge
(n = 552, 91.1 %). Regarding the criteria for including a
disease in a mass screening panel, responses were consist-
ent with the criteria introduced by Wilson and Jungner
[11] and subsequently refined [12]. The most common
responses were “diagnosable in the initial phase” (21.5 %),
“treatment must be more efficacious when administered
early” (30.9 %), “the cost of treating the disease in adults
could be unsustainable for the healthcare system” (21.5 %).
Expanded newborn screening
Nearly 80 % of respondents thought that expanded NBS
should be required by law. This would appear to reflect a
strong belief in the benefit of this service. Responses to
the question regarding the principle characteristics of ex-
panded neonatal screening were consistent with a clear
understanding of the subject. The two correct answers re-
ceived a total of 88 % of the selections; however, 40.4 % of
respondents felt that their knowledge of expanded NBS
was insufficient or poor. Interestingly, many of these re-
spondents may live in Regions that do not yet provide ex-
panded screening; nonetheless, this indicates that there is
a need for training and education so that these pediatri-
cians will be prepared to inform parents in the event that
a harmonized nationwide program is organized to offer
screening to all newborns in Italy.
Follow-up
Finally, the question regarding the presence of reference
Centers for metabolic diseases in the respondent’s Region
revealed that 537 (89.4 %) believed that there was such a
centre in their Region. To some extent, this may reflect
more on the percentage of respondents from Regions that
have such Centers, but it could also reflect confusion over
the definition of a specialist referral centre. Expanded
NBS covers diseases that require highly trained metabolic
pediatricians or geneticists. Moreover, the Center should
have an intensive care unit and pediatricians/neonatolo-
gists should be aware that neonatal onset metabolic dis-
eases like urea cycle disorders or organic acidemias may
present clinically before screening results are available.
Conclusions
Primary care pediatricians in Italy are now familiar with
NBS using the traditional panel, but some may not be fully
aware of the diseases included in expanded NBS panels. A
large majority of respondents believe that expanded NBS
should be required by law in Italy. This is an important
message from the survey. We need to work toward a uni-
form screening panel to avoid Regional disparities that
might limit the benefit of the screening itself. Clearly, this
would entail a substantial increase in the number of call-
backs and a corresponding increase in interactions between
pediatricians, specialists, laboratories and the families of af-
fected newborns. The information exchanged would be
more complex, involving lesser-known diseases. Some of
these new diseases do not follow the clear pattern seen in
phenylketonuria, where a complete absence of symptoms in
the early months is followed by serious neuropsychological
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damage. Some conditions may even remain asymptomatic
“mild cases”, complicating the interpretation of results.
Two in five survey respondents did not believe that they
had sufficient knowledge about expanded NBS. Successful
implementation of an expanded NBS program will require
resources and efficient procedures for follow-up, diagnosis
and treatment to prevent morbidity and mortality of infants
and to reduce the period of uncertainty for unaffected fam-
ilies. Pediatricians may need additional training to allow
them to fulfill the tasks of coordinating this process while
keeping families informed and reassured. The Italian
Pediatrics Society can play an important role. Collecting
and analyzing results from all Centers will allow bench-
marking and future optimization of the screening program
in our Country.
Additional file
Additional file 1: Scoring systems according to ACMG (2006) and
SIMMESN for selecting metabolic diseases to screen. ACMG score: score
reported in the 2006 ACMG report calculated by averaging the scores of at
least two experts in the field who have rated the evidence on a scale of 1 to 4
in favor of or against the inclusion of a given condition in the panel,
considering the four elements (disease, screening test, diagnosis, and
treatment). SIMMESN criteria. Strength of recommendation: A) Strong
recommendation for adoption; B) Recommendation of adoption; C)
Recommendation to not adopt; I) Evidence insufficient to make a
recommendation. Grade of evidence: 1) From well-designed and
well-conducted studies on representative populations, 2) Sufficient to
determine the effects, but limited by the number, quality or consistency of
the individual studies, by their generalizability to routine practice, or by the
indirect nature of the evidence, 3) Insufficient to determine effects due to
limitations in the number and value of the studies, to imperfections in the
design or conduct, to gaps in the chain of evidence 4) Eligible for further
pilot studies.
Abbreviation
NBS: Newborn screening.
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